clinical trial · NCT07230652
A Phase 1 MAD Study to Evaluate the Safety and Tolerability of LY03020
SchizophreniaAlzheimer's Disease PsychosisLY03020Placebo
brief summary
This is a randomized, double-blind, placebo-controlled, ascending multiple oral dose study to assess the safety, tolerability, and pharmacokinetics of LY03020 in Chinese healthy adult subjects and/or subjects with stable schizophrenia.
started
Aug 20, 2025
primary completion
Dec 31, 2025
completion
Feb 28, 2026
last updated
Nov 19, 2025
official title
A Randomized, Double-Blind, Placebo-Controlled, Dose- Ascending Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of LPM787000048 Maleate Extended-Release Tablets (LY03020) in Chinese Adult Healthy Subjects and/or Subjects With Stable Schizophrenia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol